Metformin Hydrochloride + VildagliptinThird Party Manufacturing in India

Metformin Hydrochloride + Vildagliptin is a rationally designed fixed-dose combination that targets the two core defects of type 2 diabetes: hepatic glucose overproduction and incretin system dysfunction. Metformin, a biguanide, activates AMP-activated protein kinase (AMPK) in the liver, suppressing gluconeogenesis and reducing hepatic glucose output. It also improves peripheral insulin sensitivity by enhancing glucose uptake in skeletal muscle and adipose tissue, and decreases intestinal glucose absorption. Vildagliptin, a potent and selective DPP-4 inhibitor, complements metformin's action by preventing the degradation of incretin hormones, specifically glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). By raising active GLP-1 levels, vildagliptin enhances glucose-dependent insulin secretion from pancreatic beta cells and suppresses glucagon release from alpha cells. This glucose-dependent mechanism means vildagliptin works only when blood glucose is elevated, minimizing the risk of hypoglycemia. Together, the two agents address both insulin resistance and impaired insulin secretion, providing complementary and synergistic glycemic control with a favorable safety profile and good tolerability.

Therapeutic Uses

Metformin Hydrochloride + Vildagliptin is prescribed for the treatment of:

• Type 2 Diabetes Mellitus: This combination is indicated as an adjunct to diet and exercise in patients with type 2 diabetes who are inadequately controlled on metformin monotherapy. The complementary mechanisms of action provide superior glycemic control compared to either agent alone, with significant reductions in both fasting plasma glucose and postprandial glucose levels.

• Combination Therapy Intensification: When metformin monotherapy fails to achieve HbA1c targets, the addition of vildagliptin provides effective glucose lowering without the weight gain and hypoglycemia risk associated with sulfonylureas.

• Patients Needing Beta-Cell Preservation: Vildagliptin's DPP-4 inhibition helps preserve pancreatic beta-cell function by reducing beta-cell apoptosis and promoting proliferation, particularly valuable in early-stage type 2 diabetes.

• Elderly Patients: The combination offers a favorable safety profile in elderly patients due to the low risk of hypoglycemia and weight neutrality, making it suitable for long-term diabetes management in older adults.

Why Manufacturers Choose Metformin + Vildagliptin

This fixed-dose combination addresses the growing need for combination therapy in type 2 diabetes, as most patients eventually require more than one agent to achieve glycemic targets. The combination of metformin and vildagliptin is well-established in clinical practice and is recommended by major diabetes guidelines as a preferred second-line option after metformin monotherapy. Indian manufacturers produce this combination for both domestic PCD franchise networks and export markets, with the DPP-4 inhibitor segment showing strong growth across Asia, Africa, and Latin America. The fixed-dose tablet formulation improves patient compliance by reducing pill burden.

This makes Metformin Hydrochloride + Vildagliptin a valuable addition for third party manufacturing in India, with growing demand from PCD franchise operators and export-oriented companies.